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Management of Chronic Constipation within the Community Setting 
Abstract  
Constipation is a common presenting problem within the community, but its treatment is often 
unsatisfactory. For older adults, constipation can have a gradual onset over a number of years, with 
many people “self-medicating” with over the counter laxatives and herbal products, resulting in the 
need for daily laxatives (McCrea et al, 2008 and McCormick., Flemming, and Charlton 1995). This 
article will consider best practice for the assessment, treatment and prevention of constipation in 
adults within the community.  
Definition of constipation 
Constipation is difficult to define due to the differing perception of “normal” amongst populations. 
Causes of constipation can be divided into primary (idiopathic) and secondary causes. People with 
constipation can be separated into two main categories: those with defecation difficulties (with 
normal frequency) and those with transit abnormalities (which can present as infrequent 
defaecation), (Muller-Lissner and Wald, 2010). 
Prevalence 
Despite the introduction of a diagnostic criteria (Mostafa, 2008), prevalence figures are difficult to 
interpret within research studies due to differing study populations, definitions used and whether 
pregnant women and those with underlying pathology or idiopathic constipation are included. 
Constipation is one of the most prevalent gastrointestinal complaints with UK estimates in adults 
between 8.2% to 52% (Shafe et al., 2011, Kaschick., Navck and Ostgathe, 2003 and Wald et al., 
2010). Self-reported constipation and admissions to hospital for constipation are more 
common in women than in men. The overall female-to-male ratio is approximately 3:1 
(Schmidt et al., 2015).  
 
Around half of people admitted to palliative care report constipation, with around 80% requiring 
laxatives, especially those taking opioid medications (Fallon and O'Neill, 1998 and Sykes, 2013). 
Studies are often conducted on patients with chronic constipation, however constipation can be a 
transient, short term problem, which may not be included within prevalence studies (Shafe et al., 
2011). Pregnancy increases the risk of constipation, with estimates of one in four women 
experiencing constipation (Bradley et al., 2007). It is known that prevalence increase in the older 
population, with higher rates reported in those in institutional care (Talley, 2004). The increased 
frequency of constipation in adults older than 65 years may reflect a combination of dietary 
alterations, decreases in muscle tone and exercise, and the use of medications that may 
result in relative dehydration or colonic dysmotility.  
Risk factors for constipation include: 
  
• Underlying medical condition 
• Medication 
• Toileting facilities 
• Mobility 
• Nutritional intake 
• Fluid Intake 
 Diagnostic criteria 
Constipation refers to a decrease in the frequency  and or a dificulty in passing bowel movements. 
The stool of a oerson who is constipated will be typically hard as it contains less water than normal. 
Constipation is a symptom and not a disease.    
Generally constipation is difficult to define as symptoms and the perception of what is “normal” 
varies from person to person and across cultures. “Normal” frequency of bowel movements varies, 
ranging from three bowel movements per day to three per week. With constipation often defined as 
a frequency of fewer than three bowel movements per week (Higgins and Johanson., 2004). In 
practice this can be misleading, as many people will have fewer than three bowel movements with 
no associated straining, bloating, pain or discomfort and therefore not consider themselves 
constipated. However if a person has had a generally regular frequency of bowel function that 
changes acutely and persists for a long period of time, without a known cuase, this should prompt 
them to consult a healthcare professional. Advice should be sought if a person has not opened their 
bowels for three succesive days, the fecaes is hard and the person experiences difficulty or pain on 
defeacation.   
The Rome III criteria (Mostafa, 2008) is a standardised tool to aid the diagnosis of chronic 
constipation. Diagnosis is based on two or more of the following symptoms being present for at least 
12 weeks in the previous 6 months;  
 Straining at defecation on at least a quarter of occaisions 
 Stools that are lumpy/hard  on at least one quarter of occaisions 
 A sensation of incomplete evacuation on at least one quarter of occaisions  
 Three or fewer bowel movements a week 
Chronic constipation is typically diagnosed when a person has bowel motions twice a week or less 
for two consecutive weeks, especially when other symptoms such as straining, abdominal discomfort 
and incomplete evacuation or faecal overflow are present. 
There are several pathophysiological types of chronic constipation: 
 Colonic inertia – where the movement of the bowel contents through the bowel is slowed 
 Outlet delay (or obstructed defecation) – this can be due to: 
o pelvic floor dyssynergia -where the muscles of the pelvic floor contract or fail to 
relax during defecation attempts 
o and anismus -where the external anal sphincter contracts instead of relaxing during 
defecation 
 Constipation that occurs without delayed colonic transit or outlet delay  
(Pare et al, 2007) 
Impact of constipation 
The impact of constipation on an individual’s quality of life can be significant. A systematic 
literature review by Belsey et al in 2010, demonstrated that the impact is comparable to 
other chronic long term conditions and that the mental health effects predominated over 
the physical domains.There is also a significant economic burden for both patients and 
healthcare providers. The economic burden on patients includes the cost of 
medications/prescription charges, lost/restricted days of activity (including days off work 
and lost wages) and the cost of healthcare visits (Dennison et al, 2005).   
The cost to the health service is also significant. In the UK around 500,000 GP consultations 
each year are for constipation (Norton, 2006). Constipation accounts for an estimated 10% 
of community nursing time (Norton, 2006), with 80% spending up to half a day a week 
treating and managing constipation (Larkin et al., 2008).  Studies indicate that up to 50% of 
older patients are faecally impacted (Spinzi, 2007 and Rao and Go., 2010).Faecal impaction 
often requires intervention with manual evacuation, which as well as having cost 
implications for healthcare, places the patients health at risk and causes a loss of dignity and 
distress for older people (Addison et al., 2003)   In England in 2011, 61, 162 hospital 
admissions were attributed to a primary diagnosis of constipation, with more than 40% of 
these aged 65yrs and over (Dr Foster Health, 2011). Over 17million laxative items were 
prescribed in the uk in 2013 (Health and Social Care Information Centre , 2013). The “ 
Evaluation of the Scale, Causes and Costs of Waste Medicines” (York Health Economics 
Consortium and The School of Pharmacy, University of London , 2010) report indicted that 
medicines for the gastro-intestinal system represented the most frequently wasted 
medicines. With laxatives the mostly frequently wasted medicines within care homes.     
 
Anatomy and physiology of normal bowel function 
The colon (large bowel) is a muscular tube around 1.5 metres in length, with the rectum 12-
15cm in length, opening into the anal canal. The internal wall of the colon mostly consists of 
two layers of smooth muscle. These two smooth muscle layers consist of longitudinal fibres 
in the outer layer and circular fibres in the inner layer (see figure 1 below) (Bajwa and 
Emmanuel, 2009, Emmanuel, 2004 and Long and Cheshire, 2002). The contraction of these 
two layers of muscle contributes to breaking down food, mixing it with the digestive 
secretions and propelling it forward, referred to as peristalsis. Peristalsis constricts the 
muscle and then propels the narrowed portion slowly down the length of the bowel, 
pushing anything in front of the narrowing forward. The anus contains the internal anal 
sphincter, which is composed of smooth muscle, which is not under voluntary control, and 
the external sphincter, composed of skeletal voluntary muscle (Bajwa and Emmanuel, 2009, 
Emmanuel, 2004 and Long and Cheshire, 2002).   
 
Figure 1 – Muscle layers of the large bowel 
 
 Neurological control  
A complex series of nerves control the lower bowel. The gastrointestinal tract is controlled by the 
autonomic nervous system with sympathetic and parasympathetic nerves working together. 
Innervation is the lower bowel depends on autonomic and somatic nerves. The nerves 
supplying the large intestine are via the sympathetic and parasympathetic nerves. The 
external anal sphincter is under voluntary control and is supplied by motor nerves from 
lower levels of the spinal cord (Bajwa and Emmanuel, 2009 and Emmanuel, 2004).  
The extrinsic nerve supply comprises parasympathetic, sympathetic and somatic nerves. The vagus 
nerve is parasympathetic and innervates the upper sections of the gastro-intestinal tract up to the 
splenic flexure (Bajwa and Emmanuel, 2009 and Emmanuel, 2004). The pelvic nerves carry 
parasympathetic nerve fibers from the S2-S4 levels of the spinal cord to the descending colon and 
rectum. Sympathetic nerve innervation originates from the superior and inferior mesenteric nerves 
(T9-T12) and the hypogastric nerve (T12-L2). Sympathetic innervation comes from the superior and 
inferior mesenteric nerves (T9-T12) and the hypogastric nerve (T11-L2). The hypogastric nerve sends 
out sympathetic innervation from the L1, L2, and L3 spinal segments to the lower colon, rectum, and 
sphincters. Leading to relaxation of the rectum and anal canal (Bajwa and Emmanuel, 2009 and 
Emmanuel, 2004). The somatic pudendal nerve (S2-4) innervates the pelvic floor and the external 
anal sphincter. This nerve stimulates the rectum and anal canal to contract or tighten, causing the 
internal anal sphincter to relax, allowing faeces to pass through the anus while the rectum and anal 
canal contract, assisting in defecation and is the process of emptying faeces from the bowel. The 
internal anal sphincter functions outside of conscious control (involuntary control), meaning that it 
operates in an automatic manner (Bajwa and Emmanuel, 2009 and Emmanuel, 2004). 
The bowel also has an intrinsic nervous system (known as the enteric nervous system), composed of 
the submucosal (ie, Meissner) and myenteric (ie, Auerbach) plexuses, which largely regulate 
segment-to-segment movement of the GI tract (see figure 2 below) (Bajwa and Emmanuel, 2009 
and Emmanuel, 2004).  
Figure 2 – Neurological control of the Bowel 
 
Function of the Large Bowel 
The large bowel is designed to undertake several functions including: 
• Storage of food prior to elimination 
• Absorption of remaining water, electrolytes and some vitamins 
• Synthesis of Vitamin K and some Vitamin B by colonic bacteria 
• Secretion of mucus to lubricate the faeces 
• Elimination of food residual  
The longer that faecal matter remains within the large bowel, the more water is re-
absorbed and the harder the stools become making them more difficult to pass.    
(Bajwa and Emmanuel, 2009 and Emmanuel, 2004). 
How to know when it’s time to ‘go’: 
As faeces collects in the rectum, the walls of the rectum gradually expand as the faeces build up. At 
a certain point, the brain senses that the rectum is “full,” and the urge to defecate occurs. 
The person must then adopt correct posture to facilitate bowel evacuation, which leads to a 
rise in intra-abdominal pressure. The internal and external anal sphincters relax and the 
rectum contracts to expel stool. This should lead to the passage of a soft formed stool with 
minimal effort. The sphincter then “snaps shut” after completion (Bajwa and Emmanuel, 
2009 and Emmanuel, 2004). 
 Neurogenic Bowel dysfunction 
Patients with a neurogenic bowel will have motor and sensory dysfunction resulting in 
either a reflex bowel or areflexic (flaccid) bowel. The table below provides a guide to 
distinguish between reflex bowel dysfunction areflexic dysfunction (Spinal Cord Injury 
Centres of the United Kingdom and Ireland, 2012). 
Table 1 Guide to distinguishing Motor function in Spinal Cord injured patients (taken from: 
(Spinal Cord Injury Centres of the United Kingdom and Ireland, 2012) 
Reflex bowel function  
 
Areflexic (flaccid) bowel function 
Positive anal reflex (anal wink) – visible 
contraction of anus in response to pinprick 
of surrounding skin 
No anal reflex (anal wink) 
Positive bulbo-anal reflex – contraction of 
anus in response to pressure on glans 
penis/clitoris 
Absent bulbo-anal reflex 
Injury/damage usually at or above T12 
Reflex paralysis 
Injury/damage usually L1 and below (conus 
or cauda equine, flaccid or areflexic 
paralysis) 
 
The ideal bowel movement: 
• The feeling you want to go is definite but not irresistible 
• Once you sit on the toilet there is no delay 
• No conscious effort or straining 
• The stool glides out smoothly & comfortably 
• Followed by a pleasant feeling of relief 
 
Assessment 
The first part of an assessment is to gain an overview of the person’s current pattern of 
bowel function. A baseline chart should be kept for 3-14 days depending on how often the 
person has their bowels open (see figure 3 for an example baseline bowel chart). The 
baseline also provides a useful measure of progress and success of any treatment plan. 
Figure 3 Baseline bowel chart (example) 
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The baseline chart should be used in conjunction with the Bristol stool chart (Heaton and 
Lewis, 1997) (see below)         
               
 
 
This should be accompanied by a diet (food and fluid intake) diary to establish current 


































       
 
Also consider: 
– The individual (functional and cognitive impairment) – can they sit on the toilet and 
adopt the correct position (see figure 5) without support or is assistance or a frame 
required. 
– The environment – is the environment suitable, i.e. warm, well lit, private and has 
toilet paper. 
– Underlying medical conditions (see table 1 for conditions that may cause or 
contribute to constipation) 
– Medications -A review of current medication should also be requested, especially if 
the person has recently started on any new medications (see table 2 for drugs which 
may cause or contribute to constipation). This review should include any over the 
counter (OTC) or herbal remedies the patient is taking. 
– What the patient has already tried to relieve their constipation, including OTC 
medications or herbal remedies 
 
Table 1 Conditions which may cause or contribute to constipation 
Conditions which may cause or 
contribute to constipation 
• Bowel obstruction 
• Irritable bowel syndrome 
• Cancer 
• Diverticular disease 
• Dehydration 
• Admission to hospital for any cause 
• Hypothyroidism 
• Neuromuscular disorders 





 Table 2 Drugs which may cause or contribute to constipation 
 Opioid analgesics, including compound products e.g. co-codamol, co-dydramol 
 Drugs with antimuscarinic (anticholinergic) effects including: 
 Tricyclic/SSRI/SNRI antidepressants 
 Antipsychotics 
 Antimuscarinic anti-parkinsonian drugs, e.g. orphenadrine, benzatropine, 
trihexyphenidyl and procyclidine 
 Antihistamines – especially the older sedating antihistamines e.g. 
chlorphenamine, promethazine and cyclizine 
 Antispasmodics e.g. propantheline and hyoscine 
 
 Calcium salts (note: also contained in some antacids and phosphate binders) 
 Aluminium salts (in many antacids) 
 Iron salts 
 Calcium channel blockers (mainly verapamil) 
 Phenothiazines 
 Non-steroidal anti-inflammatory drugs (NSAIDs) (although these more commonly cause 
diarrhoea) 
 5HT3 antagonists e.g. Ondansetron 
 
 
Figure 5 Correct toilet sitting position 
 
Treatment options 
The main aim of treatment is to promote a regular, predictable and comfortable bowel 
movement for the patient. Ideally this should be achieved with the modification of a 
person’s diet and lifestyle. However for many people laxatives are required. Rectal 
interventions (suppository/micro-enema, digital rectal stimulation or  digital removal of 
faeces) remain a last resort for most patients, but are the only way to manage patients with 
reflex bowel dysfunction due to spinal injury. However if the person has sensation in the 
saddle area around the perineum they are likely to have anorectal sensation. Where 
sensation is present digital interventions may be too uncomfortable and rectal stimulants 
(either suppositories or enemas) may provide a better option (Spinal Cord Injury Centres of 
the United Kingdom and Ireland, 2012). A local anaesthetic gel can also be used to increase 
patient comfort.   
No investigations are routinely required for constipation before intitiating treatment. However if a 
secondary cause is suspected, or treatment is ineffective, specialist investigations may be required 
(NICE, Clinical Knowledge Summaries, 2014). 
Before treating chronic constipation, any feacal loading/impaction must be relieved. A combination 
of oral laxatives and enemas may be required initially to remove feacal loading and impaction. 
Patients should be advised about lifestyle changes such as diet and fluid modification and the 
importance of regular meals and increasing exercise and where possible medications that can 
constipate should be adjusted (NICE, Clinical Knowledge Summaries, 2014).   
Diet and fluid modification   
Generally people should be advised to eat a balanced diet that contains grains, fruit and 
vegetables. Any increases in fibre intake should be made gradually in order to minimise 
flatulence and bloating. Adults should be aiming to eat 18-30grms of fibre per day. It can 
take as long as 4 weeks to see the effects of increasing fibre in the diet and may require 
laxatives short term, while the patient modifies their diet (National Institute for Healthcare 
Excellence (NICE) Clinical Knowledge Summaries, 2014).   There are two main types of fibre 
soluble and insoluble and patients need to be encouraged to increase their insoluble fibre to 
increase their stool weight and frequency of bowel movements  
Types of fibre: 
SOLUBLE FIBRE:  
• Effectively broken down by enzyme-producing bacteria to produce energy, gas & 
bulky stools. 
• Soluble Fibre forms a gel-like substance which binds to other substances in the gut. 
• Lowers cholesterol levels. 




• Less easily broken down by bacteria. 
• Holds water very effectively (up to 15 x its weight) therefore adds weight to stool. 
• ‘Natures Broom’ has protective effects on the gut. 
 
An adequate fluid intake (around 1.5 – 2 litres per day) is also important – particularly if a 
high fibre diet or fibre supplements have been encouraged, but this can be difficult for some 
people (NICE, Clinical Knowledge Summaries, 2014). Especially the frail or elderly. Fruits 
which are in sorbitol and fibre and fruit juices high in sorbitol, can help to treat and prevent 
constipation. Examples of fruits high in sorbitol are; prunes (and prune juice) and apricots 
(NICE, Clinical Knowledge Summaries, 2014, Stacewicz-Sapuntzakis et al, 2001 and Lo Voi et 
al, 1995). 
These recommendations are based largely on expert opinion, due to a lack of direct 
evidence from clinical trials (Heaton, 2006). Speed et al (2010) aimed to investigate the 
clinical cost effectiveness of dietary and lifestyle advice versus laxatives, unfortunatley the 
trial failed to recruit sufficient participants and therefore analysis was not possible.   
Abdominal massage 
Studies have suggested that abdominal massage produces a measurable response in the 
rectum and anus particularly for patients with neurogenic bowel dysfunction (Coggrave, 
2007 and Coggrave, 2008). It is believed that massage may trigger the somato-visceral reflexes, 
stimulate peristalsis, decrease colonic transit time and increase bowel movement frequency 
(Coggrave, 2005). Abdominal massage has also been demonstrated to aid relaxation, reduce 
discomfort and pain and improve patient’s quality of life (Lamas., Graneheim and Jacobsson, 2012) 
Laxatives 
Laxatives are recommended for patients where diet and lifestyle modifications have proved 
ineffective or while waiting for these to take effect. For those individuals taking medication that can 
constipate and that cannot be altered or stopped, those with secondary constipation and those on 
opioid medications (NICE, Clinical Knowledge Summaries, 2014). It can take several months to 
reduce the amount of laxatives taken – however the continued requirement for laxatives should be 
reviewed every three months (British Medical Association and Royal Pharmaceutical Society, 2015). 
Where laxative medication is required, recommendations are to start with a bulk forming laxative. 
However for some patients (such as the frail elderly) this may be difficult as they require a good fluid 
intake (NICE, Clinical Knowledge Summaries, 2014). 
The type of laxative required will depend on; 
– Presenting symptoms – if a patient has slow colonic transit a stimulate 
laxative may be most effective 
– Nature of complaint – depending on the patients underlying condition such 
as neurogenic bowel with multiple sclerosis or spinal injury 
– Side –effects  
– Speed of action 
– Patient acceptability 
– Compliance/concordance 
 
Types of Laxatives 
Bulk forming  
- Fybogel®, Celvevac® Normacol®, Regulan® 
 
These act like dietary fibre, by increasing the water content and faecal mass, this leads to an 
increase stool weight and frequency. Usually work within 24 -36 hours  
Stimulant 
- Senna®, Bisacodyl®, co-danthramer®, co-danthrasate®, dioctyl®, docusol® 
 
These stimulate an increase in colonic motility (peristalsis) and mucus secretion. They are 
rapid acting, usually taking effect in 8-12 hours. They are best taken in evening or at 
bedtime. Stimulant laxatives are effective when used with bowel management programmes, 
where predictable rectal contents are required prior to performing digital stimulation or 
digital removal of faeces. 
Osmotic 
- Lactulose ® and Magnesium salts  
Osmotic laxatives act by drawing fluid from the body into the bowel by osmosis. This 
increases the water content of the faeces making it softer and easier to pass. 
  
Iso-osmotic - Macrogol oral powder compound (3350) (Polyethylene glycol, PEG) 
- Cosmocol®, Laxido®,  Movicol® 
Macrogol laxatives increase stool water content and directly trigger colonic propulsive 
activity and defaecation. This has a 4 in 1 mode of action: Bulks, softens, stimulates and 
lubricates. 
Rectal stimulants 
- Bisacodyl and Glycerine suppositories 
 
Rectal stimulant can be used alone or in combination with digital stimulation and digital 
removal of decease. The advantage of suppositories for many patients is that they are 
predictable. 
(British Medical Association and Royal Pharmaceutical Society, 2015). 
Cost effectiveness  
Macrogol laxatives are increasingly being used as a first line treatment for chronic 
constipation (Ramkumar and Rao, 2005). There is also clear evidence that macrogol (PEG) is 
superior to lactulose (Lee-Robichaud et al, 2011 and Belsey., Geraint and Dixon, 2010) and ispagula 
husk (Wang et al, 2004). In two systematic reviews (Belsey., Geraint and Dixon, 2010 and Lee-
Robichaud et al, 2011), PEG has been shown to be more effective than lactulose for the treatment of 
chronic constipation. PEG showed a significant increase in mean defaecations per week when 
compared with lactulose, this was also shown in comparison with ispagula (Belsey, Geraint and 
Dixon, 2010). Tolerability to PEG was reported as generally good. In a systematic review, Guest., 
Clegg and Helter (2008) concluded that from an NHS perspective,  macrogol 4000 was cost effective 
compared with lactulose  for the treatment of chronic constipation. This is supported by Taylor and 
Guest (2010), who concluded that macrogol 3350 affords the NHS a cost-effective and more 
efficacious option than lactulose (Attar et al,1999) for the management of constipation.  
Conclusion 
Chronic constipation is a major reason for people presenting to healthcare professionals within the 
community. Chronic constipation is expensive for both patients, in distress and discomfort as well as 
time off work and the NHS, with significant amounts of community nursing staff time spent on 
treatment and management. With correct assessment the treatment of constipation can be 
improved. Although laxative use is often required to treat the initial acute constipation, 
modifications to diet and lifestyle should also be made to prevent future episodes and reduce the 
amount of laxatives required.  
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